Integra LifeSciences Holdings Corporation (IART)
After hours:
| Previous close | 62.86 |
| Open | 62.68 |
| Bid | 63.75 x 800 |
| Ask | 63.84 x 800 |
| Day's range | 61.80 - 63.86 |
| 52-week range | 61.80 - 77.40 |
| Volume | |
| Avg. volume | 382,695 |
| Market cap | 5.395B |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | 25.07 |
| EPS (TTM) | 2.54 |
| Earnings date | 23 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 78.73 |
- Simply Wall St.
Integra LifeSciences Holdings (NASDAQ:IART) jumps 4.4% this week, though earnings growth is still tracking behind five-year shareholder returns
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
- Zacks
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
- GlobeNewswire
Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repurchase
Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year.Full-year 2021 revenue is expected to be in a range of $1,541 million to $1,543 million, representing an increase of approximately 12% on a reported basis and an increase of approximately 14% on an organic basis compared to the prior year.The company is planning
